Thursday, October 4, 2012
The Wellcome Trust
has launched a program to fund early stage translational research in rare and
orphan diseases. Participation in the program, dubbed the Pathfinder Award
Scheme, requires academics or not-for-profits to pair up with an industry
partner at the outset.
Metal and metabolism
The UCL-Lilly team, led by molecular
neuroscience professor John Hardy, will build cell culture models of neurodegeneration
with brain iron accumulation (NBIA), a rare hereditary PD-like condition.
Osherovich, L. SciBX 5(39); doi:10.1038/scibx.2012.1020
Published online Oct. 4, 2012
AND INSTITUTIONS MENTIONED
Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind.
Orphan Europe S.a.r.l., Paris, France
Pfizer Inc. (NYSE:PFE), New York, N.Y.
Prana Biotechnology Ltd. (ASX:PBT; NASDAQ:PRAN), Melbourne, Victoria, Australia
Rare Disease Therapeutics Inc., Franklin, Tenn.
Structural Genomics Consortium, Oxford, U.K.
University College London, London, U.K.
University of Oxford, Oxford, U.K.
Wellcome Trust, London, U.K.